Brand J8612

XATMEP 2.5 MG/ML ORAL SOLUTION

XATMEP 2.5 MG/ML ORAL SOLUTION has a NADAC acquisition cost of $21.07, though hospitals typically charge significantly more than this benchmark price.

By Michael Glenn , Healthcare Data Analyst · Published March 15, 2026 · Updated April 3, 2026

Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.

About the analyst

Michael Glenn reviews CMS datasets and drug pricing at BillRazor Research. He focuses on NADAC acquisition costs and procedure coding accuracy. Expertise: drug pricing, NADAC data, CPT coding.

NADAC acquisition cost data

CMS drug pricing benchmarks

Updated 2026-04-03

Drug acquisition cost — XATMEP 2.5 MG/ML ORAL SOLUTION

Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.

$21.07

NADAC acquisition cost

SOLUTION

Dosage form

ORAL

Route

XATMEP is a liquid formulation of methotrexate used for treating certain cancers, autoimmune conditions, and rheumatoid arthritis. As a brand-name specialty oral solution, XATMEP typically generates higher reimbursement rates compared to standard methotrexate tablets or injections.

Check your bill amount

Enter the charge for XATMEP 2.5 MG/ML ORAL SOLUTION from your bill to compare against the NADAC acquisition cost.

No credit card required. Results in 60 seconds.

Compare your bill against the $21 NADAC acquisition cost → Scan your bill

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.

Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.